The chart below shows how AWH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AWH sees a +10.09% change in stock price 10 days leading up to the earnings, and a -8.14% change 10 days following the report. On the earnings day itself, the stock moves by -4.94%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Quarterly Revenue Increase: OvaSuite revenue for the third quarter of 2024 was $2.3 million, a 2% increase from $2.2 million of the same period last year.
OvaSuite Test Increase: The number of OvaSuite tests performed increased 4% for the third quarter of 2024 compared to 5,783 tests in the same period last year.
OvaWatch Year-Over-Year Growth: OvaWatch increased 27% year-over-year for the quarter.
Gross Margin Improvement: Our gross margins for the third quarter of 2024 improved to 60% compared to 59% for the third quarter of 2023.
R&D Expense Decrease: Research and development expenses for the quarter decreased by $90,000, or 9%, compared to the same period in 2023.
Negative
Quarterly Revenue Decline: OvaSuite revenue for the third quarter of 2024 was $2.3 million, a slight decrease from $2.4 million in the second quarter of 2024.
OvaSuite Test Increase: The number of OvaSuite tests performed increased 4% for the third quarter of 2024 compared to 5,783 tests in the same period last year.
Weather-Related Growth Impact: Our growth for the quarter was negatively impacted by severe weather, especially Hurricane Helene that devastated several of our major markets in Florida, Georgia, South Carolina, North Carolina and Tennessee in September.
Average Unit Price Decline: Our average unit price was $376 for the third quarter of 2024 compared to $383 in the third quarter of 2023.
Average Unit Price Increase: The average unit price increased 4% to $360 for the third quarter of 2024 compared to $347 in the same period last year.
Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript
AWH.O
-7.21%